The Wall Street Journal2d agobullish
Berkshire Adds to Alphabet Stake, Buys Homebuilders and Exits ConstellationGreg Abel—CEO and top stock picker—reduced the company’s portfolio in financial shares during the second quarter.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
52last 24h
1759last 7d
300● bullish (7d)
168● bearish (7d)
205publishers
Bloomberg4d agoneutral
S&P 500 Earnings Are So Good Investors Are Starting to Worry(Bloomberg) -- The latest reason to worry about the stock market is quite the doozy: Earnings growth has been too strong. Most Read from BloombergPhoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn’t DriveTrump Weighs Call for Capital Gains Tax Cuts as Midterm BoostTata Sons Chairman to Step Down, Deepening Leadership TurmoilFive Takeaways From Zuckerberg’s 6,500-Word Manifesto on AIEpstein Victim Files Cleared for Release Over Maxwell’s ProtestAs the latest reporting season nears
Motley Fool5d agoneutral
DaVita (DVA) Q2 2026 Earnings Call TranscriptMortality gains drove treatment growth despite payor mix headwinds.
Zacks11d agoneutral
DVA Q2 Earnings Call Centers on Clinical-Led Volume GrowthDaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
Moby11d agoneutral
DaVita Inc. Q2 2026 Earnings Call SummaryMoby summary of DaVita Inc.'s Q2 2026 earnings call
MarketBeat11d agoneutral
DaVita Q2 Earnings Call HighlightsDaVita (NYSE:DVA) reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access
GuruFocus.com11d agoneutral
DaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic ...DaVita Inc (DVA) reports adjusted EPS of $4.02 and reaffirms full-year guidance amid successful phosphate binder transition and expanded HD dialyzer rollout.
The Wall Street Journal12d agobearish
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall FurtherShares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
StockStory13d agoneutral
DaVita (DVA) Reports Q2: Everything You Need To Know Ahead Of EarningsDialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.
StockStory18d agoneutral
DaVita (DVA): Buy, Sell, or Hold Post Q1 Earnings?What a time it’s been for DaVita. In the past six months alone, the company’s stock price has increased by a massive 122%, reaching $235.17 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Barchart32d agoneutral
What You Need To Know Ahead of DaVita’s Earnings ReleaseDaVita is entering earnings with strong momentum as investors look for another quarter of solid execution.
The Wall Street Journal93d agoneutral
Companies Have a New AI Problem: Too Many AgentsAs it gets easier to create artificial-intelligence agents with platforms like Anthropic’s Claude Cowork , some businesses are dealing with ‘AI agent sprawl.’
Zacks96d agobearish
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin DownHIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.